GCP
TEVA icon

Garda Capital Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Garda Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157,800
Closed -$2.64M – 461
2025
Q2 		$2.64M Sell
157,800
-131,200
-45% -$2.12M 0.06% 238
2025
Q1 		$4.44M Buy
+289,000
New +$5.16M 0.11% 230
2023
Q1 		– Sell
-200,000
Closed -$1.82M – 457
2022
Q4 		$1.82M Buy
+200,000
New +$1.75M 0.1% 231

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Garda Capital Partners's TEVA Position: Q3 2025 in Review

Garda Capital Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2025, closing a stake of 12,050 shares — an estimated $202K sold.

Garda Capital Partners first reported a position in TEVA in Q1 2025 and held it in 2 quarters. The position peaked at $273K in Q1 2025. 553 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Garda Capital Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2025 after selling out during the quarter.
  • Garda Capital Partners sold 12,050 Teva Pharmaceutical Industries Limited shares in Q3 2025, an estimated $202K.
  • Garda Capital Partners first reported a position in Teva Pharmaceutical Industries Limited in Q1 2025 and held it in 2 quarters.
  • Garda Capital Partners's Teva Pharmaceutical Industries Limited position peaked at $273K in Q1 2025.
  • 553 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2025.

Based on Garda Capital Partners's 13F filing for Q3 2025, filed 10 Nov 2025.